Product Information
LEVOTHYROXINE 300 MCG TABLET is a generic product labeled by Alvogen Inc., priced at $0.1135 per EA under NDC 47781067110. Its NADAC has been published 352 times since Aug 7, 2019.
FDA first approved this application on Oct 24, 2002. Its Orange Book therapeutic-equivalence code is AB1,AB2,AB3,AB4 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 ug/1
Manufacturer
Alvogen Inc.NDC
47781067110
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
4/22/2026
Active Ingredients
LEVOTHYROXINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021116FDA Approved
10/24/2002
TE Code
AB1,AB2,AB3,AB4
On Market Since
5/7/2019
Pharmacological Classes
Price Statistics
The NADAC for LEVOTHYROXINE 300 MCG TABLET has been published 352 times since Aug 7, 2019, and over the history we have for it it has declined 83.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1135 per EA |
|---|---|
| All-time high | $0.7249 (Mar 11, 2020) |
| All-time low | $0.0715 (Jul 17, 2024) |
| 52-week high | $0.1234 |
| 52-week low | $0.1098 |
| Median price | $0.1620 |
| Average price | $0.2919 |
| Largest weekly change | +78.9% (Aug 21, 2024) |
| Weeks tracked | 352 |
| Tracking since | Aug 7, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
+3.4%
1Y
-2.5%
3Y
+0.1%
5Y
-74.9%
All
-83.8%
Last surveyed Apr 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alvogen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levothyroxine sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Thyroxine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOTHYROXINE 300 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOTHYROXINE 300 MCG TABLET, manufactured by Alvogen Inc., is $0.1135 per EA (NDC 47781067110), effective Apr 29, 2026.
How has the price of LEVOTHYROXINE 300 MCG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOTHYROXINE 300 MCG TABLET has declined 83.8%. It has been tracked across 352 weekly CMS publications since Aug 7, 2019.
What are the highest and lowest recorded NADAC prices for LEVOTHYROXINE 300 MCG TABLET?
Since Aug 7, 2019, the NADAC for LEVOTHYROXINE 300 MCG TABLET has ranged from a low of $0.0715 (Jul 17, 2024) to a high of $0.7249 (Mar 11, 2020), with a median of $0.1620 per EA.
Are there cheaper alternatives to LEVOTHYROXINE 300 MCG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVOTHYROXINE 300 MCG TABLET, is $0.1043 per EA — about 8% below LEVOTHYROXINE 300 MCG TABLET.
Who manufactures LEVOTHYROXINE 300 MCG TABLET?
LEVOTHYROXINE 300 MCG TABLET (NDC 47781067110) is labeled by Alvogen Inc., and CMS classifies it as a generic product.